News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,459 signal articles · 145 in last 24h · 154,156 total before filter · latest 1h ago

145last 24h

874last 7d

145● bullish (7d)

96● bearish (7d)

214publishers

All Macro211 Earnings107 M&A125 Regulatory21 Product21 Analyst17

✕ clear all filtersticker: GILDsentiment: bearishSentiment:bullish neutral bearish show all (incl. clickbait)

Barrons.com140d agobearish

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut?

Gilead Sciences beat analysts’ earnings and revenue expectations in its latest quarter. Gilead logged adjusted earnings of $2.03 a share, ahead of the $1.91 consensus among analysts polled by FactSet. Gilead’s top-line growth rested heavily on Biktarvy, its blockbuster HIV treatment, which accounted for nearly half of total revenue as sales rose 8% to $3.4 billion.

GILD

Reuters140d agobearish

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

By Deena Beasley LOS ANGELES, May 7 (Reuters) - Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for

GILD